Oasmia Pharmaceutical AB (publ) Bokslutskommuniké för räkenskapsåret 1 maj 2018 – 30 april 2019
June 28, 2019 01:30 ET
|
Oasmia Pharmaceutical AB
HÄNDELSER FJÄRDE KVARTALET Genomförd riktad nyemission om cirka 165 MSEK före emissionskostnaderNy styrelse valdes på extra bolagsstämma den 19 marsNy styrelse inleder genomlysning av situationen i...
The Board of Oasmia has decided to report certain transactions to the Swedish Economic Crime Authority and to appoint a special examiner
June 28, 2019 01:30 ET
|
Oasmia Pharmaceutical AB
The Board of Oasmia has decided to report certain suspicious transactions that has been made by the company during several years to the Swedish Economic Crime Authority. In connection with a tax...
Oasmia meddelar VD-skifte
June 28, 2019 01:30 ET
|
Oasmia Pharmaceutical AB
Sven Rohmann, MD PhD MBA, har idag utsetts till tf VD för Oasmia Pharmaceutical AB. Han antar sin nya roll den 1 juli 2019. I mars valdes Sven Rohmann in i styrelsen och i april tillträdde han som...
Oasmia announces change of CEO
June 28, 2019 01:30 ET
|
Oasmia Pharmaceutical AB
Sven Rohmann, MD PhD MBA, has today been appointed as acting CEO of Oasmia Pharmaceutical AB. He assumes his new role July 1, 2019. Since March 2019 Sven Rohmann has been a member of the Board of...
Oasmia presenterar bokslut och status avseende styrelsens genomlysning via audiocast den 28 juni
June 26, 2019 02:00 ET
|
Oasmia Pharmaceutical AB
Oasmia kommer att hålla en audiocast och telefonkonferens fredagen den 28 juni klockan 09:00 (CET) för genomgång av bolagets bokslut för räkenskapsåret 2018/2019 samt presentera status i styrelsens...
Oasmia presents full-year report and status in the Board's review through audiocast on June 28
June 26, 2019 02:00 ET
|
Oasmia Pharmaceutical AB
Oasmia will hold an audiocast and telephone conference on Friday 28 June at 09:00 (CET) to present the company's full-year report for the financial year 2018/2019 and the status of the board's...
Två studier genomförda i Oasmia Pharmaceuticals Docecal-program
June 25, 2019 02:00 ET
|
Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB (NASDAQ:OASM) presenterar idag resultaten från två kliniska studier av läkemedelskandidaten Docecal i patienter med metastaserande bröstcancer. Docecal är en nyutvecklad...
Two studies finalized in Oasmia Pharmaceutical’s Docecal programme
June 25, 2019 02:00 ET
|
Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB (NASDAQ: OASM) reports on the results from the two clinical studies using Docecal in patients with metastatic breast cancer. Docecal is a newly developed formulation of...
Oasmia senarelägger publiceringen av Q4-rapporten och bokslutskommunikén till den 28 juni
May 15, 2019 02:00 ET
|
Oasmia Pharmaceutical AB
Styrelsen i Oasmia har beslutat att senarelägga publiceringen av rapporten för fjärde kvartalet och bokslutskommunikén 2018/2019 från 5 juni 2019 till 28 juni 2019. Förseningen är ett resultat av den...
Oasmia postpones the release of the Q4 and year-end report to 28 June
May 15, 2019 02:00 ET
|
Oasmia Pharmaceutical AB
The Board of Oasmia has decided to postpone the release of the fourth quarter and year-end 2018/2019 report from 5 June 2019 to 28 June 2019. The delay is a result of the ongoing review...